NDATOPICALCREAM
Approved
Sep 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
6/8 — Strong
DENAVIR (penciclovir) by Viatris (2) is dna polymerase inhibitors [moa]. Approved for herpes labialis. First approved in 1996.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DENAVIR (penciclovir) is a topical cream containing a nucleoside analog DNA polymerase inhibitor approved in 1996 for herpes labialis (cold sores). It works by inhibiting viral DNA synthesis in herpesvirus-infected cells, reducing viral replication and symptom duration.
$0.889MPart D
LOE ApproachingDeclining
As a mature, declining product with minimal commercial spend, career opportunities are limited and likely focused on cost management and market stabilization rather than growth initiatives.
Mechanism of Action
DNA Polymerase Inhibitors
Pharmacologic Class:
Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor
Indications (1)
Clinical Trials (2)
Non-inferiority Comparison of Efficacy and Safety of Penciclovir 10mg/g to Acyclovir 50mg/g in the Treatment of Recurrent Herpes Labialis
Started Feb 2012
76 enrolled
Herpes Labialis
A Comparative Study of the Efficacy of Penciclovir 10mg/g (1%) Cream in Preventing the Appearance of Classical Lesion in Recurrent Cold Sore Sufferers
Started Dec 2008
126 enrolled
Cold Sore
Worked on DENAVIR at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.